Oftalmopatía tiroideadeterminación de parámetros de actividad clínica de la oftalmopatía tiroidea como factor pronóstico de respuesta al tratamiento inmunosupresor

  1. A Belzunce-Manterola
  2. PJ García-Gómez
  3. M Casellas-Bravo
  4. H Heras-Mulero
  5. J Moreno-Montañés
Journal:
Archivos de la Sociedad Española de Oftalmologia

ISSN: 0365-6691

Year of publication: 2005

Volume: 80

Issue: 12

Pages: 705-712

Type: Article

DOI: 10.4321/S0365-66912005001200005 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Archivos de la Sociedad Española de Oftalmologia

Sustainable development goals

Abstract

Objective: To determine the usefulness of the clinical, biochemical and thyroid imaging parameters in patients with thyroid-associated ophthalmopathy, in predicting their response to immunosuppressive treatment. Methods: This retrospective study of 16 patients with thyroid ophthalmopathy considered a number of variables including sex, age, thyroid hormone levels, treatment of the thyroid dysfunction, clinical activity score (CAS), severity (NOSPECS) of the ophthalmopathy, signs in standardized A-mode ultrasonography, in CAT and/or NMR, and previously used treatments and their effectiveness. Results: The average age of the patients was 50.81 (S.D: 11.89) years; there were 5 males (31.3%) and 11 females (68.8%). The ophthalmopathy was classified as active in 10/16 patients (62.5%) and inactive in 6/16 (37.5%); and as moderate in 9/16 (56.25%) and severe in 7/16 (43.75%) according to the severity defined in NOSPECS. Ultrasonography was diagnostic in 100% of the cases. The severity decreased significantly (p ≤ 0.05), however the clinical activity decrease did not reach significance (p=0.38) during immunosuppressive therapy. Better results were obtained during treatment of patients with a higher CAS (p=0.04) and in those with more severe ophthalmopathy (p=0.02). There was a tendency for the patients with higher levels of TSI to respond better to the treatment (p=0.06). Conclusions: The CAS is the best parameter to quantify the activity of the disease and predicting the response to treatment. The higher the CAS and the more severe the ophthalmopathy, the better the response to treatment. No association existed between thyroid function and the activity or severity of the ophthalmopathy; or the effectiveness of treatment.

Bibliographic References

  • Bradley, EA. (2001). Graves ophthalmopathy. Curr Opin Opthalmol. 12. 347-351
  • Prummel, MF, Wiersinga, WM, Mourits, MP, Koornneef, L, Berghout, A, van der Gaag, R. (1990). Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch Intern Med. 150. 1098-1101
  • Bartalena, L, Marcocci, C, Bogazzi, F, Manetti, L, Tanda, ML, Dell’Unto, E, Bruno-Bossio, G. (1998). Relation between therapy for hyperthyroidism and the course of Graves´ ophthalmopathy. N Engl J Med. 338. 73-78
  • Mourits, MP, Kooerneef, L, Wiersinga, WM, Prummel, MF, Berghout, A, van der Gaag, R. (1989). Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol. 73. 639-644
  • Werner, SC. (1977). Modification of the classification of the eye changes of Graves’ disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab. 44. 203-204
  • Prummel, MF, Gerding, MN, Zonneveld, FW, Wiersinga, WM. (2001). The usefulness of quantitative orbital magnetic resonance imaging in Graves` ophthalmopathy. Clin Endocrinol. 54. 205-209
  • Mourits, MP, Prummel, MF, Wiersinga, WM, Koornneef, L. (1997). Clinical activity score as a guide in the management of patients with Graves’ opthalmopathy. Clin Endocrinol. 47. 9-14
  • Gerding, MN, Prummel, MF, Wiersinga, WM. (2000). Assessment of disease activity in Graves’ opthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol. 52. 641-646
Data source: Dialnet